Insulin degludec (IDeg) is a new basal insulin in development with a flat, ultra-long action profile that may permit dosing using a simplified titration algorithm with less frequent self-measured blood glucose (SMBG) measurements and more simplified titration steps than currently available basal insulins.
These dosimetric advantages of proton plans may permit further dose escalation with lower risk of complications.
Conformal treatment planning spares adjacent normal tissues reducing treatment-related side effects and may permit safe dose escalation.
The quantitative assay described here will be useful for evaluating less-toxic retinoids and also combinations of agents that may permit lower doses of retinoids to be effective in allowing myoblast differentiation in the presence of TGF-β1.
Extended release preparations of stimulants have durations of action between 6 to 14 hours, which may permit once-daily dosing, although an adult may still need twice daily dosing of medication for a 12-16 hour day.
Methods that afford simultaneous transmission and emission scanning by taking advantage of time-of-flight information [10], for example, may permit lower radiation doses and shorter imaging times.
The clinical use of atosiban to prevent the oxytocin-stimulated increase in uterine activity associated with labor in combination with nimesulide may permit reduction of the dose of nimesulide used to a level that has minimal impact on fetal well-being.
The present data suggest that combining T-oligos with low dose IR may permit safer and more effective radiotherapy of breast cancer and potentially other malignancies.
Intermittent dosing schedules may permit the use of antiangiogenic TKIs with reduced systemic toxicity and equivalent therapeutic benefit.
These findings suggest that the injection of biotinylated chA7Fab complexed with NCS followed by avidin may be safer and may permit the administration of larger doses of NCS without the subsequent development of renal failure.
